Nuvectis Pharma

Nuvectis Pharma

Yahoo Finance • 2 months ago

Catalyst Watch: SpaceX initiations, Sun Valley Conference, PepsiCo earnings

[Headquarters of SpaceX in Hawthorne, California] Sven Piper Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next wee... Full story

Yahoo Finance • 2 months ago

At a glance: stocks gapping down premarket

[Wall Street New York City] aluxum/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-down moves before the bell Tuesday. US stock index futures (SPX [https://seekingalpha.com/symbol/SPX]) saw modest gains early Tu... Full story

Yahoo Finance • 2 months ago

Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock

FORT LEE, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditio... Full story

Yahoo Finance • 2 months ago

Apogee Therapeutics, BitFuFu rise premarket; AbbVie gains after deal

U.S. stock futures edged higher on Monday as investors monitored corporate dealmaking activity and developments in the biotechnology and cryptocurrency sectors. Biotech stocks were in focus in premarket trading after a major acquisition a... Full story

Yahoo Finance • 2 months ago

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

The transaction transforms Nuvectis into a late-stage clinical development company by expanding its pipeline into complement-mediated diseases with the in-licensing of a Complement Factor B inhibitor (CFBi [NXP100]) and also enhances the o... Full story

Yahoo Finance • 8 months ago

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Fort Lee, NJ, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unme... Full story

Yahoo Finance • 9 months ago

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

Fort Lee, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT, the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious con... Full story

Yahoo Finance • 11 months ago

ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan... Full story

Yahoo Finance • 11 months ago

Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors

Nuvectis Pharma, Inc. Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of seri... Full story

Yahoo Finance • 12 months ago

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Fort Lee, NJ, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatmen... Full story

Yahoo Finance • last year

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and ALK inhibitors in pat... Full story

Yahoo Finance • last year

Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers; initiation of Phase 1b program is immin... Full story

Yahoo Finance • last year

Nuvectis Pharma stock price target lowered to $10 at H.C. Wainwright

Investing.com - H.C. Wainwright lowered its price target on Nuvectis Pharma (NASDAQ:NVCT) to $10.00 from $15.00 on Monday, while maintaining a Buy rating on the stock. The company’s shares, currently trading at $7.00, have declined over... Full story

Yahoo Finance • last year

Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study

Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable diseases; thrombocytopenia successfully managed... Full story

Yahoo Finance • last year

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment... Full story

Yahoo Finance • last year

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR) conference demonstrated robust pharmacodynamic response and acceptable safety at clinically relevant dose... Full story

Yahoo Finance • 2 years ago

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option

FORT LEE, NJ, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unme... Full story

Yahoo Finance • 2 years ago

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

FORT LEE, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of un... Full story

Yahoo Finance • 2 years ago

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

FORT LEE, NJ, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unme... Full story

Yahoo Finance • 3 years ago

Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

Phase 1b Study of NXP800 in Patients with Platinum Resistant, ARID1a-Mutated Ovarian Carcinoma is Ongoing Initiated the Phase 1a Dose Escalation Study of NXP900 in Patients with Advanced Solid TumorsNXP800 Granted Orphan Drug Designation f... Full story